Adaptive Biotechnologies Corp. launched T-Detect Lyme, a T-cell-based clinical test to detect immune response activated by Borrelia burgdorferi, the bacterial species of spirochete that causes Lyme disease. The CLIA-validated laboratory-developed test (LDT) is meant to help diagnose early Lyme disease in adults showing signs and symptoms of the tick-borne illness.